Wanwei Zheng

Dr. Wanwei Zheng

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZZZiqiang Zhang
Ziqiang Zhang
HXHongyuan Xue
Hongyuan Xue
YDYuanqiang Dong
Yuanqiang Dong
JZJun Zhang
Jun Zhang
YPYida Pan
Yida Pan
JDJianjun Du
Jianjun Du
The GKN2 is a secretory protein, whose levels decrease in gastric cancer. The present study aimed to investigate the expression, function and mechanism of action of GKN2 in gastric cancer. Molecular biology assays were performed to elucidate the function and underlying mechanisms of GKN2 in gastric cancer under stress-induced condition in vivo and in vitro. Clinical specimens were used to assess the correlation of GKN2 and prognosis. We found that overexpression of GKN2 significantly enhanced apoptosis and growth arrest in vitro. GKN2 expression increased in gastric cancer cells exposed to hydrogen peroxide and promoted reactive oxygen species-induced mitochondrial dysfunction and resulted in increased cell apoptosis via inhibition of NF-κB signaling pathway and activation of JNK signaling pathway through the direct interaction of GKN2 with Hsc70. Trefoil factor 1 might contribute to the tumor suppressing effects of GKN2. MiR-216a downregulated GKN2 expression. GKN2 also inhibited xenograft tumor growth and was an independent and significant prognostic factor for patients with gastric cancer treated with oxaliplatin. Taken together, our data indicate that GKN2 may increase sensitivity of GC cells to the drugs which increase ROS levels in tumors. Inhibition of the interaction between GKN2 and Hsc70 could attenuate the effects induced by GKN2. GKN2 overexpression could be used to determine the subgroup of patients to obtain the more favorable outcome of oxaliplatin treatment and may be used as biomarker of the prognosis of this cancer.

15 November 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
YSYuru Shen
Yuru Shen
BZBin Zhong
Bin Zhong
WZWanwei Zheng
Wanwei Zheng
DWDan Wang
Dan Wang
LCLin Chen
Lin Chen
JLJie Liu
Jie Liu
Liposomal drug delivery systems have revolutionized traditional cytotoxic drugs. However, the relative instability and toxicity of the existing liposomal drug delivery systems compromised their efficacy. Herein, we present Rg3-lipo, an innovative drug delivery system using a glycosyl moiety–enriched ginsenoside (Rg3). This system is distinguished by its glycosyl moieties exposed on the liposomal surface. These moieties imitate human cell membranes to stabilize and evade phagocytic clearance. The Rg3-lipo system loaded with paclitaxel (PTX-Rg3-lipo) demonstrated favorable bioavailability and safety in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys. With its glycosyl moieties recognizing tumor cells via the glucose transporter Glut1, PTX-Rg3-lipo inhibited gastric, breast, and esophageal cancers in human cancer cell lines, tumor-bearing mice, and patient-derived xenograft models. These glycosyl moieties selectively targeted myeloid-derived suppressor cells (MDSCs) through the glucose transporter Glut3 to attenuate their immunosuppressive effect. The mechanism study revealed that Rg3-lipo suppressed glycolysis and downregulated the transcription factors c-Maf and Mafb overcoming the MDSC-mediated immunosuppressive microenvironment and enhancing PTX-Rg3-lipo’s antitumor effect. Taken together, we supply substantial evidence for its advantageous bioavailability and safety in multiple animal models, including nonhuman primates, and Rg3-lipo’s dual targeting of cancer cells and MDSCs. Further investigation regarding Rg3-lipo’s druggability will be conducted in clinical trials.

3 December 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
ZLZhongguang Luo
Zhongguang Luo
WLWenshuai Li
Wenshuai Li
WZWanwei Zheng
Wanwei Zheng
YSYixiang Shi
Yixiang Shi
MYMaolin Ye
Maolin Ye
JLJie Liu
Jie Liu
Background: Epigenetic modifications are crucial in tumourigenesis, yet the changes in novel epigenetic regulators like 5‐hydroxymethylcytosines (5hmC) during the evolution of gastric premalignant lesions remain poorly understood. This study aims to investigate the implications of 5hmC in the progression from gastric premalignant lesions to gastric adenocarcinoma (GAC).Methods: To our knowledge, we conducted the largest and longest longitudinal study of a Chinese population with gastric precursor lesions, involving 29,176 patients with gastritis who underwent gastroscopy and biopsy between 2001 and 2015, with follow‐up until 1 August, 2022. The median follow‐up time was 12.2 years, and the overall GAC incidence rate was 0.82%. Genome‐wide mapping of 5hmC in gastric premalignant lesions from a subset of individuals was performed using the 5hmC‐Seal assay, including 21 samples that progressed to GAC during follow‐up and 48 non‐progressed age‐ and sex‐matched controls.Results: We identified 213 differentially modified gene bodies, primarily concentrated in pathways related to cell division, cell cycle, energy metabolism, inflammation and tumourigenesis. An exploratory study was conducted to summarize a 5hmC‐based epigenetic model for predicting cancer progression using multivariable logistic regression and machine learning. The nine‐gene model showed an area under the curve of 87.5% (95% confidence interval: 72%–100%) in the validation samples (one of three), which were set aside before model training.Conclusions: This study is the first to explore the 5hmC molecular landscape in gastric premalignant lesions, suggesting relevant pathways implicated in their evolution to GAC as well as the feasibility of exploiting genome‐wide 5hmC mapping in assessing the risk of future cancer progression.Key points: A largest longitudinal follow‐up study of gastric precursor lesions in Chinese patients. Revealing novel 5hmC molecular landscape linked to gastric premalignant lesions. The feasibility of an innovative 5hmC‐based predictive model for assessing gastric cancer progression risk.

15 July 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
BWBangting Wang
Bangting Wang
ZLZhongguang Luo
Zhongguang Luo
WZWanwei Zheng
Wanwei Zheng
JZJun Zhang
Jun Zhang
JLJie Liu
Jie Liu
Cite this article as: Wang B, Lou Z, Zheng W, Zhang J, Liu J. Capillary hemangioma in the ileum: Obscure small-bowel bleeding in an elderly person. Turk J Gastroenterol 2018; 29: 520-1.

26 February 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
QCQiuming Chen
Qiuming Chen
SMShaocong Mo
Shaocong Mo
LZLinhai Zhu
Linhai Zhu
MTMuhu Tang
Muhu Tang
JCJun Cheng
Jun Cheng
HJHu Jian
Hu Jian

29 October 2023 in Clinical and Translational Medicine
Verified
Journal Article
Open access
YTYujen Tseng
Yujen Tseng
LLLingxi Lin
Lingxi Lin
SMShaocong Mo
Shaocong Mo
SZSuhan Zhao
Suhan Zhao
QSQiwei Shen
Qiwei Shen
JLJie Liu
Jie Liu